Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723597 | 0.89 | CYP3A4 (0.50) | CYP3A4SCN9ACYP17A1CYP2C9MAPK1 | |
| SCHEMBL15294420 | 0.82 | CYP3A4 (0.50) | CYP3A4CYP1A2 | |
| SCHEMBL2723699 | 0.80 | CYP3A4 (0.48) | CYP3A4NPC1RAB9AHPGDS | |
| SCHEMBL6116398 | 0.79 | CYP17A1 (0.40) | CYP3A4SCN9APDE10AMAOAMAOB | |
| SCHEMBL2724779 | 0.75 | CYP3A4 (0.42) | CYP3A4SCN9ACYP17A1CYP2C9 | |
| SCHEMBL2723714 | 0.72 | CYP3A4 (0.40) | CYP3A4 | |
| SCHEMBL15297242 | 0.71 | CYP17A1 (0.48) | CYP3A4SCN9ACYP17A1CYP2C9SCN10A | |
| SCHEMBL5020170 | 0.68 | CYP17A1 (0.52) | CYP3A4SCN9ACYP17A1CYP2C9SCN10A | |
| SCHEMBL9071312 | 0.68 | NPC1 (0.43) | CYP3A4SCN9APDE10AMAOAMAOB | |
| SCHEMBL15294419 | 0.67 | CYP3A4 (0.76) | CYP3A4CYP17A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | claimed |
| EP-2632903-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | claimed |
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2651905-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2632903-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012082746-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885SCN9A 2026/4885PDE10A 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.